Revenue Growth - Revenue for the six months ended September 30, 2021, reached RMB 501.93 million, representing a 62.3% increase compared to RMB 309.17 million in the same period last year[11]. - The life sciences solutions segment saw a significant growth of 106.3%, with revenue increasing from RMB 70.58 million to RMB 145.63 million[11]. - The health management platform and solutions segment experienced a remarkable growth of 642.6%, with revenue rising from RMB 25.65 million to RMB 190.44 million[11]. - As of September 30, 2021, the total revenue reached RMB 501.9 million, representing a year-on-year growth of 62.3%[13]. - The total revenue for the big data platform and solutions segment was RMB 157.9 million, with a gross margin of 41.7%, representing a year-on-year increase of 4.9 percentage points[19]. - Revenue from life sciences solutions rose by 106.3% to RMB 145.6 million, driven by an increase in active customers and higher average revenue per active customer[25]. - The health management platform and solutions segment experienced a revenue increase of 642.6% year-over-year, reaching RMB 190.4 million for the six months ended September 30, 2021[22]. Profitability and Losses - The gross profit for the period was RMB 144.07 million, a 64.4% increase from RMB 87.63 million year-on-year[11]. - The company reported an operating loss of RMB 442.21 million, which is a 72.7% increase in losses compared to RMB 256.10 million in the previous year[11]. - The adjusted net loss for the period was RMB 321.50 million, reflecting a 93.9% increase compared to RMB 165.81 million in the same period last year[11]. - The period loss decreased by 62.9% from RMB 1,192.4 million to RMB 442.5 million, mainly due to the conversion of convertible redeemable preferred shares and convertible bonds after the IPO[37]. - The net loss for the six months ended September 30, 2021, was RMB 442,542 thousand, compared to a net loss of RMB 1,192,357 thousand in the same period of 2020, indicating a reduction in losses by 62.9%[87]. - The net loss attributable to the company's owners was RMB 440,768 thousand for the six months ended September 30, 2021, compared to a net loss of RMB 1,192,614 thousand in the same period of 2020, indicating a significant reduction in losses[122]. Customer Base and Market Expansion - The number of active clients in the life sciences segment increased from 108 to 127, indicating a growing customer base[9]. - The number of top-tier research hospitals served increased from 76 to 78, demonstrating an expansion in the company's hospital partnerships[9]. - The active customer count for life sciences solutions increased to 127, adding 19 new customers during the reporting period[13]. - The overall revenue retention rate for all clients was 133%, while the retention rate for core pharmaceutical, biotechnology, and medical device clients was 140%[21]. - The company aims to deepen its understanding of various disease areas, expand its customer base, and enhance data processing and machine learning capabilities[23]. - The company plans to leverage its disease insights and expert network to provide effective health management solutions[24]. Research and Development - The company has developed a real-world data clinical research platform with a contract value of several tens of millions, aimed at accelerating the approval of fast-track drugs and medical devices[15]. - A predictive model for identifying infection risk in ICU patients was developed in collaboration with a top three hospital, effectively tested on over 1,600 cases[16]. - The company’s clinical trial patient enrollment efficiency improved by 100%, while the screening failure rate decreased by 60% compared to client-defined requirements[20]. - Research and development expenses grew by 94.7% from RMB 98.6 million to RMB 192.0 million, with the percentage of R&D expenses to revenue rising from 31.9% to 38.2%[32]. - The company has allocated RMB 30 million for research and development in the upcoming year to support innovation and product development[171]. Financial Position and Cash Flow - As of September 30, 2021, the company had cash and cash equivalents of RMB 4,219.5 million, down from RMB 4,605.6 million as of March 31, 2021[41]. - The company reported a net cash position as of September 30, 2021, with a debt-to-equity ratio not applicable, compared to 99.0% as of September 30, 2020[44]. - The company experienced a foreign exchange loss of RMB 60.2 million for the six months ended September 30, 2021, compared to a foreign exchange gain of RMB 179.5 million in the same period in 2020[45]. - The net cash used in operating activities was RMB (281,329) thousand for the six months ended September 30, 2021, compared to RMB (22,068) thousand for the same period in 2020[92]. - Cash and cash equivalents at the end of the period reached RMB 4,214,443 thousand, significantly up from RMB 1,132,999 thousand year-over-year, reflecting an increase of 272.5%[93]. Corporate Governance and Shareholder Information - The board is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[54]. - The company has complied with all applicable provisions of the corporate governance code, with the exception of the separation of the roles of Chairman and CEO[55]. - The board will regularly review the company's situation and consider adopting a dividend policy when appropriate[55]. - The company did not make any significant investments or acquisitions during the six months ended September 30, 2021[42]. - No interim dividend has been proposed for the six months ending September 30, 2021, as the board believes it is not appropriate to adopt a dividend policy at this stage[53]. Stock Options and Employee Incentives - The company aims to attract and retain top talent through the Pre-IPO Employee Stock Option Plans[65]. - The total number of unexercised stock options as of September 30, 2021, was 140,854,805 shares, representing approximately 14.42% of the issued shares[65]. - The company granted 4,842,450 stock options to employees under the post-IPO stock option plan as of September 30, 2021[144]. - The average exercise price of stock options granted during the period was USD 4.443, with a total of 145,526,255 stock options outstanding at the end of the period[145]. - The post-IPO share option plan has a remaining validity of approximately nine years from the listing date[74]. Future Outlook - The company provided a future outlook, projecting a revenue growth of 20% for the next fiscal year, driven by new product launches and market expansion strategies[171]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[171]. - A strategic acquisition of a local tech firm is anticipated to enhance the company's technological capabilities and broaden its service offerings[171]. - A new product line is set to launch in Q1 2022, expected to contribute an additional RMB 50 million in revenue within the first year[171].

User Growth and Customer Base - Active individual users increased from less than 30,000 to over 5 million[14] - The number of active life science customers rose from 74 to 108[14] - The number of top-tier research hospitals served increased from 71 to 76[14] - The coverage of regulatory agencies and policymakers expanded from 14 to 19[14] - The number of clients for life sciences solutions grew to 108, an increase of 34 clients from the previous year[23] - The health management platform has over 5 million paid users who have made at least one purchase as of March 31, 2021[30] - The number of active clients increased from 74 to 108 within a year, with core pharmaceutical, biotech, and medical device clients growing from 55 to 80[29] Financial Performance - Total revenue for the fiscal year 2021 reached RMB 867.036 million, representing a year-on-year growth of 55.4%[21] - Revenue from health management solutions surged by 353.1% to RMB 252.129 million, compared to RMB 55.648 million in 2020[21] - Gross profit increased by 123.4% to RMB 327.336 million, with a gross margin of 37.8%, up 11.5 percentage points year-on-year[21][23] - The company reported an annual loss of RMB 3.695 billion, a 144.5% increase compared to RMB 1.511 billion in 2020[21] - Revenue increased by 55.4% from RMB 558.1 million for the fiscal year ended March 31, 2020, to RMB 867.0 million for the fiscal year ended March 31, 2021[32] - Revenue from life sciences solutions rose by 79.3% from RMB 102.8 million to RMB 184.3 million, driven by an increase in active customers from 74 to 108[32] - Revenue from health management platform and solutions surged by 353.1% from RMB 55.6 million to RMB 252.1 million, primarily due to increased income from platform-based solutions[32] Research and Development - The company aims to enhance real-world research to achieve inclusive precision medicine[19] - The company is focused on improving data infrastructure capabilities to support the healthcare industry's transition to data-driven intelligence[18] - The company has developed high-quality disease models to support precise diagnosis and efficient drug development[18] - The company aims to enhance data processing capabilities and deepen understanding of various disease areas while expanding its customer base and exploring international market opportunities[31] - The company plans to optimize disease mapping and produce research-grade insights and knowledge for various disease areas[31] Technology and Data Solutions - The company has established a COVID-19 big data intelligent platform in collaboration with a well-known research hospital in Wuhan[18] - The YiduCore data infrastructure supports high-quality data applications in various scenarios, enhancing the value of data for clients and partners[24] - YiduCore's data infrastructure covers over 500 medical institutions across more than 20 provinces in China, processing over 1.7 billion medical records from over 400 million patients[27] - The big data platform, launched in 2015, connects with existing hospital systems to provide insights for medical research, clinical diagnosis, and hospital management[143] - Life sciences solutions offer analytics-driven clinical development and real-world evidence-based research to pharmaceutical and biotechnology companies[144] - The health management platform provides personalized health management services, integrating traditional medical treatment with out-of-hospital care and lifestyle interventions[145] Governance and Compliance - The company is committed to complying with relevant laws and regulations, with no significant violations reported during the reporting period[64] - The company faces several risks, including the ability to manage growth and expansion, keep up with rapid technological changes, and comply with data protection laws[62] - The company has implemented a comprehensive anti-bribery and anti-corruption policy, ensuring compliance with relevant laws and regulations[156] - There were no judicial cases related to corruption, fraud, or money laundering during the reporting period[157] - The company has established a risk management framework that includes risk assessment, identification, analysis, response, and monitoring to enhance core competitiveness[153] Employee and Corporate Culture - The total number of employees as of March 31, 2021, was 1,201, with 834 located in Beijing, 146 in Shanghai, and 221 in other locations[54] - As of March 31, 2021, approximately 47% of employees have a medical background, and about 38% have a background in artificial intelligence and technology, representing increases of 33.1% and 17.0% year-over-year, respectively[55] - The company emphasizes employee health and safety, providing free annual health check-ups and adhering to national safety regulations, with no work-related fatalities reported during the period[186] - The company has established a comprehensive welfare system, including social security contributions for retirement, medical, unemployment, work injury, and housing funds, along with supplementary medical insurance covering five direct relatives[181] - The company promotes equal employment opportunities and opposes any form of employment discrimination based on gender, age, nationality, color, religion, or disability[180] Corporate Social Responsibility - The company has donated over RMB 6 million to various institutions for medical research, artificial intelligence research, education, and youth development during the reporting period[199] - The company received the "Caring Unit" honor from the Guizhou Poverty Alleviation Foundation for its active participation in poverty alleviation efforts[199] - The company continues to engage in poverty alleviation by procuring high-quality green agricultural products from Guizhou for the Spring Festival[200] - The company has implemented various training programs aimed at enhancing employee knowledge and skills, including general skills training and leadership training[198] - The company actively participates in corporate social responsibility initiatives, focusing on community support and development[199] Intellectual Property and Innovation - The company registered a total of 860 patents, with 249 new patents added during the reporting period[165] - The company emphasizes the importance of intellectual property protection and has established a patent management system to encourage innovation[165] - The company has obtained multiple information security management system certifications, including ISO/IEC 27001:2013 and ISO/IEC 27017:2015[159] - The company has established an information security committee responsible for overseeing all information security work[161] Leadership and Management - Yang Jing was appointed as CFO in September 2017 and President in January 2019, overseeing finance, legal, marketing, HR, operations, and investment activities[107] - Dr. Yan Jun has been the Chief Technology Officer since December 2017, responsible for the overall technology strategy and development of AI technologies[109] - The management team has extensive experience in technology and finance, with backgrounds in leading firms like Microsoft and GIC[107][109] - The company has a strong leadership team with key positions held by co-founders, including Mr. He Zhi as Chief Innovation Officer and Mr. Xu Jiming as Senior Vice President of Life Sciences Solutions[114]